Following Nobel Prize-winning chemist David Baker’s recipe for cooking an antidote to cobra venom using artificial intelligence (AI) could be faster and more effective than currently available methods. The ingredients and steps can be found in a new study published by the University of Washington scientist in collaboration with the Technical University of Denmark. They are ready for the next steps in preclinical trials.

Following Nobel Prize-winning chemist David Baker’s recipe for cooking an antidote to cobra venom using artificial intelligence (AI) could be faster and more effective than currently available methods. The ingredients and steps can be found in a new study published by the University of Washington (UW) scientist in collaboration with the Technical University of Denmark. They are ready for the next steps in preclinical trials.

The Feinstein Institutes for Medical Research has been awarded a 5-year, $2.9 million grant from the National Institutes of Health (NIH) to investigate the potential of human ghrelin as a medical countermeasure against radiation-induced gastrointestinal syndrome.

In a recently published article, researchers from the University of Central Florida and collaborators reported developing a novel multiorgan microphysiological system (MPS) to simulate acute opioid overdose and recovery, addressing key challenges in opioid crisis research.

Sparian Biosciences Inc. has been awarded a $19.5 million, 5-year grant to fund development of SBS-226 from IND submission through phase I development. SBS-226 is a first-in-class dual μ-opioid receptor partial agonist and δ-opioid receptor full antagonist in development for opiate use disorder and opiate withdrawal syndrome.

Grifols SA has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to test investigational ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sulfur mustard exposure.

Epivario Inc. has been awarded a small business innovation research (SBIR) grant of $275,000 from the National Institute on Drug Abuse (NIDA) to advance research toward the development of a novel epigenetic regulator as a treatment for opioid use disorder.

Addex Therapeutics Ltd. and Indivior plc have announced the selection of clinical candidates from their γ-aminobutyric acid subtype B (GABA-B) positive allosteric modulator (PAM) research collaboration.

Researchers from the Basque Center for Cooperative Research in Biosciences (CIC bioGUNE) have demonstrated that inhibiting posttranslational modification of proteins with NEDD8, a process called neddylation, was able to prevent liver damage induced by acetaminophen overdose.